Novo Nordisk India has formed a strategic partnership with Emcure Pharma to launch Poviztra (semaglutide injection 2.4 mg) in India, targeting weight management and cardiovascular risk reduction for patients with overweight or obesity.

Poviztra will complement the earlier launch of Wegovy in June 2025, providing a second brand for the same GLP-1 therapy. The collaboration aims to expand availability in regions where Novo Nordisk India’s direct distribution is limited, leveraging Emcure’s established marketing and distribution network across the country.

Clinical trials indicate that approximately one in three participants on semaglutide achieve weight loss exceeding 20%, underlining the therapy’s efficacy. The partnership is designed to ensure broader access to safe, high-quality treatment, supporting patient adherence and clinical outcomes across India’s diverse markets.

Under the agreement, Emcure Pharma will act as the exclusive distributor, overseeing commercialisation and marketing, while Novo Nordisk continues to provide its innovation in GLP-1 therapy. The collaboration aligns with ongoing efforts to address chronic obesity and associated medical risks, expanding the reach of globally recognised pharmaceutical interventions.

Senior Vice President of Novo Nordisk APAC, Jay Thyagarajan, emphasised the scale of unmet medical needs in India and the role of GLP-1 therapies in providing effective weight management solutions. Satish Mehta, CEO of Emcure Pharma, highlighted the company’s capability to deliver these treatments to patients across India, leveraging local expertise and infrastructure.

Semaglutide has been extensively studied in STEP and SELECT obesity programmes and benefits from nearly a decade of real-world evidence, encompassing 38 million patient years of exposure. The launch of Poviztra reinforces the adoption of GLP-1 therapy in India, enhancing treatment options in a growing market for obesity care.

Discover how this partnership is shaping obesity treatment in India by exploring the full story.